Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
29.8M
-
Shares change
-
+895K
-
Total reported value, excl. options
-
$509M
-
Value change
-
+$22.2M
-
Put/Call ratio
-
0.59
-
Number of buys
-
69
-
Number of sells
-
-46
-
Price
-
$17.10
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q2 2020
171 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.8M shares
of 54.8M outstanding shares and own 54.35% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.77M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.7M shares), FARALLON CAPITAL MANAGEMENT LLC (2.3M shares), VANGUARD GROUP INC (2.26M shares), Carmignac Gestion (2.07M shares), FIRST MANHATTAN CO (1.91M shares), Chescapmanager LLC (1.48M shares), BANK OF AMERICA CORP /DE/ (1.01M shares), STATE STREET CORP (1M shares), and ETF MANAGERS GROUP, LLC (902K shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.